CD274 and non-small cell lung carcinoma: (15) reported median OS of 21.0 months and rwPFS of 10.8 months for 169 patients with metastatic nonsquamous NSCLC, PD-L1 ≥50%, ECOG PS 0–1 who initiated first-line ICI-chemotherapy from 24 October 2016 through February 2019, similar to our findings and indeed with possible overlap of individual patients, as their study used the Flatiron Health database and covered the span of first-line therapy initiation in our study (11 May 2017 through 31 January 2019).